

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Chimpanzee adenovirus vectors for vaccine development	<p>Human, primate and mouse studies suggest chimpanzee adenovirus vectors could be used in vaccines. In nonhuman primates, a replication-deficient chimpanzee adenovirus serotype 3 (ChAd3) vector encoding an HIV antigen elicited an antigen-specific T cell response. In healthy volunteers, a ChAd3 vector encoding an HCV antigen and a ChAd63 vector encoding a <i>Plasmodium falciparum</i> antigen each induced T cell responses against their respective antigens. Clinical trials of the chimpanzee adenovirus vector-based malaria and HCV vaccines are ongoing.</p> <p>The University of Oxford is running a Phase II trial of Okairos AG's ChAd63 vector-based malaria vaccine AdCh63-MVA (formerly PlaMavax).</p> <p>SciBX 5(4); doi:10.1038/scibx.2012.110 Published online Jan. 26, 2012</p>	Multiple patent applications filed covering chimpanzee adenovirus vectors and specific vaccine applications; available for licensing	<p>Colloca, S. <i>et al. Sci. Transl. Med.</i>; published online Jan. 4, 2012; doi:10.1126/scitranslmed.3002925</p> <p>Contact: Alfredo Nicosia, Okairos s.r.l., Rome, Italy e-mail: nicosia@okairos.com</p>